RAD51 and familial pancreatic carcinoma: Whether KLF5 binds to the Rad51 promoter to stimulate its gene expression and whether Rad51 can enhance the ability of pancreatic cancer cells to resist survival pressure from chemotherapeutic agents such as gemcitabine remain to be determined.